The company reported positive efficacy results, but also revealed allegations that an investigator had failed to adhere to trial protocol and was alleged to have fabricated emails to cover their tracks.
Execs at BioXcel Therapeutics, Inc. were bullish on data from the Phase III TRANQUILITY II study of Igalmi (dexmedetomidine) in Alzheimer’s disease-related agitation, but problems at a trial site that enrolled a large percentage of the study’s participants cast a shadow over the announcement, and the company may have a difficult time getting out from under it.
BioXcel announced 29 June results from the trial of Igalmi, also known as BXCL501, showing that the study met its...
The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.
